Prevents malaria. ANDA 200856, held by Heritage. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 200856 (Doxycycline Hyclate), held by Heritage, was first approved by FDA on Apr 30, 2013, with 0 approved supplements and 0 published complete response letters.
Doxycycline hyclate delayed-release tablets are a tetracycline-class drug indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 30, 2013 | Original application | Approved | None posted |
| Doxycycline HyclateEQ 75MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Rx |
| Doxycycline HyclateEQ 100MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Rx |
| Doxycycline HyclateEQ 150MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Rx |
| Doxycycline HyclateEQ 200MG BASE · tablet, delayed release;oral | Doxycycline Hyclate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters